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COPDAbstract Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
are both common and often fatal. Lack of an accurate prognostic tool that can accurately predict
inhospital mortality and help clinicians triaging patients to the appropriate level of care is a chal-
lenge. Toward this aim, the Dyspnea, Esinopenia, Consolidation, Acidemia and atrial Fibrillation
(DECAF) Score is needed to be assessed against other available scores.
Patients and methods: Two hundred patients with primary diagnosis of AECOPD were included.
They were subjected to thorough medical history taking, full clinical examination, plain chest
X-ray, routine laboratory investigations, ECG, ABGs analysis, assessment of DECAF Score, Acute
Physiology and Chronic Health Evaluation (APACHE II) score, COPD and Asthma Physiology
Score (CAPS) and CURB-65 score. Inhospital mortality was recorded.
Results: Twenty-ﬁve (12.5%) patients died in hospital. The DECAF Score showed an excellent
discrimination for inhospital mortality (AUROC= 0.83) and performed signiﬁcantly better for the
prediction of inhospital mortality than: APACHE II Score (AUROC= 0.68, DECAF vs
APACHE II p= 0.03); and the COPD and Asthma Physiology Score (CAPS) (AUROC= 0.65,
p= 0.01). Furthermore, DECAF was a signiﬁcantly stronger predictor of inhospital mortality than
CURB-65 for the subgroup of patients with radiological consolidation (AUROC= 0.87 vs 0.65,
p= 0.02).
Conclusion: The DECAF Score is a simple and effective clinical tool that can risk stratify hos-
pitalized patients with AECOPD and could therefore help clinicians managing this fatal condition.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.d.
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Acute exacerbations of chronic obstructive pulmonary disease
(AECOPD) are both common and often fatal [1]. In-hospital
mortality of 4–30% has been reported in patients with
AECOPD requiring hospitaliation [1–3]. A robust clinical pre-
diction tool, developed from a large prospective cohort of
unselected admissions, could assist decisions regarding: loca-
tion of care; early escalation of care; appropriateness for
end-of-life care; and suitability for early supported hospital
discharge and therefore could help to reduce morbidity and
mortality and direct the most efﬁcient use of resources [1].
In stable COPD, prognostic indices have been thoroughly
investigated and tools predicting mortality risk, such as the
BODE Score, are well established [4]. However, prognostic
research in exacerbations requiring hospitalization has been
limited, and there appears to be little common ground between
predictors of mortality in stable disease and during AECOPD
[5]. Moreover, none of the prognostic scores developed in sta-
ble disease have been tested on hospitalized patients, and most
require clinical measurements not routinely available at hospi-
tal admission. Of the prognostic scores proposed for use in
AECOPD requiring hospitalization, most were derived in
highly selected, [6–9] rather than unselected, patients [10,11].
AECOPD are often complicated by radiographic consolida-
tion especially in patients receiving ventilatory support [12].
Currently, in patients hospitalized with AECOPD complicated
by consolidation, the CURB-65 (Confusion, Urea, Respira-
tory Rate, Blood pressure, Age > 65) community acquired
pneumonia prognostic score [13] is often used to risk assess
and guide antibiotic therapy [14]. However, it has been recently
shown that the use of CURB-65 in patients with AECOPD
and consolidation is suboptimal [15]. Hence, the Dyspnea,
Esinopenia, Consolidation, Acidaemia and atrial Fibrillation
(DECAF) score was ﬁrst introduced by Steer et al. [1]. The tool
is simple to administer at the bedside, using indices routinely
available on admission. The value of the DECAF Score as a
clinical prediction tool that can accurately risk stratify all
patients with AECOPD is needed to be assessed against other
available scoring systems in our locality.
Patients and methods
Patients
This study was carried out at the Respiratory ICU and Chest
Department, Zagazig University Hospitals during the period
from October 2010 to April 2013. It included 200 AECOPD
patients with a mean age of 69.3 ± 8; they were 102 males
and 98 females. Criteria for exclusion were: previous inclusion
in the study; malignancy; or a primary reason for admission
other than AECOPD.
Methods
All studied patients were subjected to the following:
1- Thorough medical history.
2- Full clinical examination (general and local examination).
3- Plain Chest X- ray (postero-anterior or antero-posterior
view according to circumstances).4- Routine laboratory investigations:
- Complete blood picture (CBC)
- Liver functions
- Kidney functions
- Serum electrolytes (Na, K, Cl)
5- Arterial blood gases’ analysis (ABGs).
6- Diagnosis of AECOPD according to Global Initiative
for Chronic Obstructive Lung Disease (GOLD) criteria
[16] supported by spirometric evidence of airﬂow
obstruction (forced expiratory volume in one second
(FEV1)/forced vital capacity (FVC) < 0.70) when clini-
cally stable; with clinical criteria of exacerbation includ-
ing increased dyspnea, increased sputum volume or
sputum purulence.
7- Stable-state dyspnea was assessed using the extended
Medical Research Council (MRC) dyspnea (eMRCD)
Score [15]; this subdivides patients too breathless to
leave the house unaided (traditional MRCD5) into those
able independently to manage washing and/or dressing
(eMRCD5a) and those requiring assistance with both
(eMRCD5b).
8- Assessment of Acute Physiology And Chronic Health
Evaluation II (APACHE II) Score [17], COPD And
Asthma Physiology Score (CAPS) [7] and CURB-65
Score [13].
9- Assessment of the DECAF Score according to Steer
et al. [1].
Variable Score
-Dyspnea
eMRCD 5a 1
eMRCD 5b 2
-Esinopenia (<0.05·103/dl) 1
-Consolidation 1
-Acidemia (pH <7.30) 1
-Atrial Fibrillation 1
Total DECAF Score 6
DECAF, Dyspnea, Esinopenia, Consolidation, Acidaemia and atrial
Fibrillation; eMRCD, extended MRC dyspnea.10- The presence of atrial ﬁbrillation was conﬁrmed by ECG
at the time of hospital admission.
11- Assessment of outcome which was either inhospital
death or discharge.Statistical analysis
Statistical analysis was performed with the SPSS statistical
software package version 19 (SPSS Inc., Chicago, IL, USA).
P-value < 0.05 was considered signiﬁcant.
Results
Two hundred patients with AECOPD were recruited with a
mean age of 69.3 ± 8; they were 102 males and 98 females.
In total, 25 (12.5%) patients died during their hospital stay.
DECAF score in predicting hospital mortality in patients with AECOPD 37Table 1 shows the socio-demographic data of all studied
patients. There were statistically signiﬁcant differences between
survivors and non survivors regarding age, being housebound,
FEV1, eMRCD and being on long term oxygen therapy.
Table 2 shows that the presence of cerebrovascular disease,
atrial ﬁbrillation and renal comorbidity was statistically signif-
icantly different in non survivors when compared with
survivors.
Table 3 shows statistically signiﬁcant differences between
survivors and those who died in hospital as regards BMI,
respiratory rate, diastolic blood pressure and the presence of
radiological consolidation, purulent sputum, ineffective cough
and lower limb edema.
Table 4 shows comparison between survivors and non sur-
vivors as regards admission arterial blood gases’ values. There
were statistically signiﬁcant differences between the two stud-
ied groups regarding pH and paCO2.
Table 5 shows statistically signiﬁcant differences between
the two studied groups as regards serum levels of potassium,
urea, creatinine, glucose, CRP and albumin. Also, hemoglobinTable 1 Socio-demographic data of the studied patients.
Parameter Survivors (no = 175
Age in years 68.5 ± 8
Sex: M/F 90/85
Housebound, No.(%) 53 (30.3%)
No. of AECOPD in previous year 2.75 ± 1
FEV1 (% of predicted) 45 ± 14.3
eMRCD, median (range) 4 (3–5a)
Long-term oxygen therapy, no (%) 20 (11.4)
Core-pulmonale, No. (%) 18 (10.3%)
Home nebulized therapy, no (%) 25 (14.3%)
Table 2 Comorbidity in the studied patients.
Comorbidity Survivors (no = 175)
Cerebrovascular disease 20 (11.3%)
Ischemic heart disease 54 (30.9%)
Hypertension 65 (37.1%)
Diabetes 26 (14.9%)
Atria ﬁbrillation 15 (8.6%)
Renal comorbidity 9 (5.1%)
Table 3 Comparison between the studied groups as regards admiss
Parameter Survivors (no = 175)
Purulent sputum 105 (60%)
Ineﬀective cough 20 (11.4%)
Lower limb edema 45 (25.7%)
Acute confusion 18 (10.3%)
Herat rate/min 100.3 ± 21.2
Systolic blood pressure (mm Hg) 140 ± 28
Diastolic blood pressure (mm Hg) 77.5 ± 15.7
Respiratory rate/min 24.5 ± 5.7
Temperature (c) 37 ± 0.6
BMI (kg/m2) 25 ± 5.9
Radiological consolidation 55(31.4%)level and esinophil count were signiﬁcantly lower in non survi-
vors than survivors.
Table 6 shows predictors of inhospital mortality in hospi-
talized patients with AECOPD. Extended Medical Research
Council Dyspnea score 5b (eMRCD5b) was the most
powerful predictor while, BMI was the least powerful one.
Parameters were ordered according to the regression coefﬁ-
cient (B).
Table 7 shows inhospital mortality rates according to each
grade of the DECAF score with relevant sensitivity and spec-
iﬁcity: DECAF 0–1 (‘low risk’; inhospital mortality = 3.37%);
DECAF 2 (‘moderate risk’; mortality = 7.7%); and DECAF
3–6 (‘high risk’; mortality = 37%).
Table 8 & Fig. 1 show comparison between area under
receiver operator characteristic (ROC) curves (AUROC) of
DECAF (AUROC= 0.83), APACHE II (AUROC= 0.68)
and CAPS (AUROC= 0.65) scores for predicting inhospital
mortality. There were statistically signiﬁcant differences when
comparing DECAF vs APACHE II (p= 0.03) and DECAF
vs CAPS (p= 0.01).) Non survivors (no = 25) P-Value
75.3 ± 10 <0.001
12/13 0.83
20 (80%) <0.001
3 ± 0.7 0.29
38 ± 11.6 0.02
5a (5a–5b) <0.001
9 (36%) 0.003
3 (12%) 0.73
4 (16%) 0.77
Non survivors (no = 25) P-Value
9 (36%) 0.003
7 (28%) 1.00
10 (40%) 0.83
4 (16%) 0.77
10 (40%) <0.001
5 (20%) <0.001
ion clinical and radiological data.
Non survivors (no = 25) P-Value
9 (36%) 0.03
10 (40%) <0.001
9 (36%) 0.34
10 (40%) <0.001
102.5 ± 22.1 0.63
136.2 ± 29.5 0.53
70.3 ± 17.9 0.036
28.1 ± 6.6 0.004
36.8 ± 0.4 0.11
21 ± 6 0.001
17(68%) <0.001
Table 4 Comparison between the studied groups as regards admission arterial blood gas values.
Parameter Survivors (no = 175) Non survivors (no = 25) P-Value
pH 7.42 ± 0.04 7.34 ± 0.09 <0.001
paO2 (mm Hg) 65.3 ± 9.5 63.1 ± 12.3 0.30
paCO2 (mm Hg) 43.5 ± 8.3 49 ± 16.3 0.008
HCO3 (mEq/L) 28 ± 5.9 29 ± 6.4 0.21
Oxygen saturation (%) 92 ± 5 92 ± 6 0.99
Table 5 Comparison between the studied groups as regards admission laboratory investigations.
Parameter Survivors (no = 175) Non survivors (no = 25) P-value
Sodium (mEq/l) 136.4 ± 4.6 136.8 ± 4.8 0.69
Potassium (mEq/l) 4.3 ± 0.5 4.6 ± 0.6 0.007
Chloride (mEq/l) 98.6 ± 8.9 98 ± 6.2 0.75
Urea (mmol/l) 6.5 ± 2.1 10.3 ± 3.8 <0.001
Creatinine (mg/dl) 0.92 ± 0.21 1.04 ± 0.43 0.02
Albumin (g/dl) 3.9 ± 0.45 3.5 ± 0.52 <0.001
Glucose (mg/dl) 126 ± 18 135 ± 25 0.03
Hemoglobin (g/dl) 13.8 ± 1.8 12.6 ± 2.2 0.003
CRP (mg/dl) 5.6 ± 3.6 8.8 ± 5.8 <0.001
White cell count (·103/dl) 11.9 ± 3.6 13.3 ± 4.2 0.08
Neutrophil count (·103/dl) 9.2 ± 3.4 11.3 ± 4.1 0.005
Esinophil count (·103/dl) 0.1 ± 0.1 0.03 ± 0.03 <0.001
Table 6 Predictors of hospital mortality in patients hospital-
ized with AECOPD.
Variable value B Odds ratio (95% CI) p
eMRCD5a 1.68 5.3 (1.9–14.9) <0.001
eMRCD5b 2.04 7.8 (2.7–22.3) <0.001
Consolidation 1.53 4.6 (1.9–11.4) <0.001
pH< 7.30 1.47 4.3 (1.8–10.3) <0.001
Esinopenia < 0.05 · 103/dl 1.3 3.7 (1.6–8.9) 0.003
AF 0.008 1.16 3.2 (1.4–7.5) 0.008
Albumin < 3.5 g/dl 1.02 2.8 (1.2–6.5) 0.02
Ineﬀective cough 0.93 2.5 (1.0–6.0) 0.033
Cerebrovascular disease 0.89 2.4 (1.0–5.7) 0.039
BMI < 18.5 kg/m2 0.86 2.4 (1.0–5.5) 0.047
38 R. Nafae et al.Fig. 2 shows a statistically signiﬁcant difference between
AUROC of DECAF and CURB-65 scores (0.87 vs 0.65;
p= 0.02) in a subgroup of patients with consolidation.
Discussion
Despite improvements in care, death during hospitalization for
AECOPD is a challenging issue. In the UK in 2008, almost 1 in
12 people admitted with a COPD exacerbation died during
their hospital stay [18]. In the U.S. in 1996, about 1 in 40 peo-
ple hospitalized with COPD exacerbations died in-hospital [2].
This could be reﬂecting a different threshold for hospital
admission and care between the countries.
This study showed a mortality rate of 12.5% among
patients hospitalized with AECOPD, a result that lies within
the range of 4–30% that has been reported in patients with
AECOPD requiring hospitalization [1–3]. The variability in
published mortality rates for patients with COPD admitted
for acute respiratory failure suggests that signiﬁcant heteroge-
neity exists within this population. It is likely that differences
in patient characteristics, more than in quality of care, account
for much of the variability. The relatively small size of many of
the previous studies makes them more susceptible to these con-
siderations [19].
Identifying upon admission those at higher risk of dying
during their hospitalization could be useful for triaging
patients to the appropriate level of care, deciding aggressive-
ness of therapies, and timing safe discharges. So, Steer et al.
[1] derived the DECAF Score––Dyspnea, Esinopenia, Consol-
idation, Acidemia, and atrial Fibrillation––tying to accurately
predict inhospital mortality for patients with AECOPD [20].
The DECAF Score is a simple prognostic tool, incorporating
clinical and laboratory information available routinely on
admission in patients hospitalized with AECOPD [1].In accordance with the results obtained by Son et al. [21] and
Steer et al. [1] the current work illustrated that the DECAF
Score showed an excellent discrimination for inhospital mortal-
ity (AUROC= 0.83). Furthermore, the DECAF Score per-
formed signiﬁcantly better for the prediction of inhospital
mortality than: the Acute Physiology and Chronic Health Eval-
uation (APACHE) II prognostic index (AUROC= 0.68,
DECAF vs APACHE II p= 0.03); and the COPD and Asthma
Physiology Score (CAPS) (AUROC= 0.65, p= 0.01); which
have been proposed as useful predictive instruments in
AECOPD (ﬁgure 1and Table 8).
In this study, DECAF was a signiﬁcantly stronger predictor
of inhospital mortality than CURB-65 for a subgroup of
patients with radiological consolidation (AUROC= 0.87 vs
0.65, p= 0.02) (Fig. 2). Similar results were previously
obtained by Steer et al. [1].
Roche et al. [11] derived a predictive score from 794
patients attending an emergency department with AECOPD.
Table 8 Comparison ofAUROC betweenDECAF,APACHE
II and CAPS scoring systems.
Score AUROC P value in comparison with DECAF
DECAF 0.83 –
APACHE II 0.68 0.03
CAPS 0.65 0.01
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Figure 2 Receiver operator characteristic curves of DECAF and
CURB-65 Scores for inhospital mortality in patients with
consolidation.
Table 7 DECAF score and hospital mortality.
DECAF Score No Hospital mortality,
no (%)
Sensitivity Speciﬁcity
0 44 1 (2.8%) 1 0
1 45 2 (4.8%) 0.96 0.25
2 65 5 (7.7%) 0.88 0.49
3 30 7 (23.3) 0.68 0.83
4 12 7 (58.3%) 0.40 0.97
5 4 3 (75%) 0.12 0.99
6 0 0 – –
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tal mortality (AUROC= 0.79) but, it included subjectively
assessed signs of clinical severity. The DECAF Score per-
formed more strongly in this study (AUROC= 0.83) com-
pared to the score described by Roche et al. moreover, the
parameters included in the DECAF Score are objective with
little potential for variable interpretation.
More than one third of our patients showed co existing
radiological consolidation with a statistically signiﬁcant differ-
ence when comparing survivors with non survivors (p< 0.001)
(Table 3). Moreover, consolidation was one of the strongest
predictors of inhospital mortality in this study (Table 6)
(p< 0.001). So, it was logic to be incorporated as a compo-
nent of the DECAF Score.
AECOPD are often complicated by radiographic consoli-
dation [12,18]. Practice varies over whether such individuals0 
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Figure 1 Receiver operator characteristic curves of DECAF,
APACHE II and CAPS Scores for inhospital mortality in all
patients.are included under the diagnosis of AECOPD, but most stud-
ies of prognosis in AECOPD requiring hospitalization have
not excluded patients with complicating consolidation
[6,7,10,11,22]. Furthermore, CT scanning in AECOPD often
shows consolidation not visible by plain radiography [23,24]
and the severity of airway obstruction and spectrum of patho-
gens in pneumonic and non-pneumonic exacerbations are sim-
ilar [25]. Pneumonic AECOPD are not simply treated as
pneumonia, but require speciﬁc management of the AECOPD,
including controlled oxygen therapy, corticosteroids, nebulized
bronchodilators and, if respiratory acidemia is present, non-
invasive ventilation [26]. Therefore, the practice of not exclud-
ing such patients was adopted in this work.
Most of the predictors associated with higher inhospital
mortality in Table 6 are consistent with previously published
studies in AECOPD: increasing age [2,11]; dyspnea sever-
ity[11,15]; low BMI [1,22]; low pH [3,22]; cough effective-
ness[27]; coexistent consolidation [15,25]; and chronic
comorbidities both cardiovascular and non-cardiovascular
including atrial ﬁbrillation and cerebrovascular disease [1,28].
Holland et al. [29] reported that esinopenia (<0.04 · 103/
dl) was associated with a higher inhospital mortality in
AECOPD, but the study population was small (n= 65). Our
results show that esinopenia is a strong predictor of inhospital
mortality (p= 0.003) (Table 6). It has previously been shown
in an animal model that esinopenia accompanies the response
to acute infection and inﬂammation [30], independent of adre-
nal glucocorticosteroids [31], and may be a useful marker of
sepsis in patients who are receiving intensive care [32,33]. In
AECOPD, the strong prognostic inﬂuence of eosinopenia
may reﬂect the severity of the accompanying acute inﬂamma-
tory response [1].
The DECAF Score shows promise for the risk stratiﬁcation
of patients hospitalized with AECOPD [1]. In the present
work, the death rates for each grade of the DECAF Score
(Table 7) suggest the following risk categories: DECAF 0–1
(‘low risk’; inhospital mortality = 3.37%); DECAF 2 (‘moder-
ate risk’; mortality = 7.7%); and DECAF 3–6 (‘high risk’;
mortality = 37%). Findings of the current study suggest that
40 R. Nafae et al.near half (44.5%) of the patients hospitalized with AECOPD
can be classiﬁed as low risk (DECAF 0–1) of inhospital mor-
tality and might therefore potentially be suitable for early sup-
ported discharge. On the other hand, a high DECAF Score
(P3) might be used as a guide to early escalation of care.
In conclusion, the DECAF Score is simple, effective and
quick to calculate clinical tool that can accurately risk stratify
hospitalized patients with AECOPD and could therefore help
clinicians managing this common and fatal condition.
References
[1] J. Steer, J. Gibson, S.C. Bourke, The DECAF Score: predicting
hospital mortality in exacerbations of chronic obstructive
pulmonary disease, Thorax 67 (2012) 970–976.
[2] S.P. Patil, J.A. Krishnan, N. Lechtzin, et al, In-hospital
mortality following acute exacerbations of chronic obstructive
pulmonary disease, Arch. Intern. Med. 163 (2003) 1180–1186.
[3] A. Bustamante-Fermosel, J.M. De Miguel-Yanes, M. Duffort-
Falco´, et al, Mortality-related factors after hospitalization for
acute exacerbation of chronic obstructive pulmonary disease: the
burden of clinical features, Am. J. Emerg.Med. 25 (2007) 515–522.
[4] B.R. Celli, C.G. Cote, J.M. Marin, et al, The body-mass index,
airﬂow obstruction, dyspnea, and exercise capacity index in
chronic obstructive pulmonary disease, N. Engl. J. Med. 350
(2004) 1005–1012.
[5] J. Steer, J. Gibson, S.C. Bourke, Predicting outcomes following
hospitalization for acute exacerbations of COPD, QJM 103
(2010) 817–829.
[6] M. Confalonieri, G. Garuti, M.S. Cattaruzza, et al, A chart of
failure risk for noninvasive ventilation in patients with COPD
exacerbation, Eur. Respir. J. 25 (2005) 348–355.
[7] M.J. Wildman, D.A. Harrison, C.A. Welch, et al, A new
measure of acute physiological derangement for patients with
exacerbations of obstructive airways disease: the COPD and
Asthma Physiology Score, Respir. Med. 101 (2007) 1994–2002.
[8] A. Ruiz-Gonzalez, D. Lacasta, M. Ibarz, et al, C-reactive
protein and other predictors of poor outcome in patients
hospitalized with exacerbations of chronic obstructive
pulmonary disease, Respirology 13 (2008) 1028–1033.
[9] A. Anton, R. Guell, J. Gomez, et al, Predicting the result of
noninvasive ventilation in severe acute exacerbations of patients
with chronic airﬂow limitation, Chest 117 (2000) 828–833.
[10] Y.P. Tabak, X. Sun, R.S. Johannes, et al, Mortality and need
for mechanical ventilation in acute exacerbations of chronic
obstructive pulmonary disease: development and validation of a
simple risk score, Arch. Intern. Med. 169 (2009) 1595–1602.
[11] N. Roche, M. Zureik, D. Soussan, et al, Predictors of outcomes
in COPD exacerbation cases presenting to the emergency
department, Eur. Respir. J. 32 (2008) 953–961.
[12] Davidson C. (2010): Adult Non-Invasive Ventilation Audit
Summary Report. The British Thoracic Society, 2011.
[13] W.S. Lim, M.M. van der Eerden, R. Laing, et al, Deﬁning
community acquired pneumonia severity on presentation to
hospital: an international derivation and validation study,
Thorax 58 (2003) 377–382.
[14] W.S. Lim, S.V. Baudouin, R.C. George, et al, BTS guidelines
for the management of community acquired pneumonia in
adults: update 2009, Thorax 64 (Suppl. 3) (2009) iii1–iii55.
[15] J. Steer, E.M. Norman, O.A. Afolabi, et al, Dyspnoea severity
and pneumonia as predictors of in-hospital mortality and early
readmission in acute exacerbations of COPD, Thorax 67 (2012)
117–121.[16] Global Initiative for Chronic Obstructive Lung Disease
(GOLD) for the diagnosis, management Strategy and
prevention of chronic obstructive lung disease (updated 2010).
Available at: http://www.goldcopd.com.
[17] W.A. Knaus, E.A. Draper, D.P. Wagner, et al, APACHE II: a
severity of disease classiﬁcation system, Crit. Care Med. 13
(1985) 818–829.
[18] Royal College of Physicians, British Thoracic Society, British
Lung Foundation (2008): Report of the National Chronic
Obstructive Pulmonary Disease Audit 2008: Clinical Audit of
COPD Exacerbations Admitted to Acute NHS Trusts across the
UK. London: Royal College of Physicians, 2008.
[19] M. Nevins, S. Epstein, Predictors of Outcome for Patients With
COPD Requiring Invasive mechanical Ventilation, Chest 119
(2001) 1840.
[20] Ley B (2012): DECAF Score Predicts COPD Exacerbation
Mortality, But Needs Validation. PulmCCM; Available at:
http://pulmccm.org/main/2012/critical-care-review/how-
dangerous-is-this-patients-copd-exacerbation-decaf-score-may-
help-predict-thorax/.
[21] J.H. Son, J.Y. Lee, Y.M. Yang, et al, Utility of the DECAF
score in patients admitted to emergency department with acute
exacerbation of chronic obstructive pulmonary disease, Korean
J. Crit. Care Med. 28 (4) (2013) 255–265.
[22] F. de la Iglesia, J.L. Diaz, S. Pita, et al, Peak expiratory ﬂow rate
as predictor of inpatient death in patients with chronic obstructive
pulmonary disease, South. Med. J. 98 (2005) 266–272.
[23] H. Syrjala, M. Broas, I. Suramo, et al, High-resolution
computed tomography for the diagnosis of community-
acquired pneumonia, Clin. Infect. Dis. 27 (1998) 358–363.
[24] J.T. Hagaman, G.W. Rouan, R.T. Shipley, et al, Admission
chest radiograph lacks sensitivity in the diagnosis of community-
acquired pneumonia, Am. J. Med. Sci. 337 (2009) 236–240.
[25] D. Lieberman, D. Lieberman, Y. Gelfer, et al, Pneumonic vs
nonpneumonic acute exacerbations of COPD, Chest 122 (2002)
1264–1270.
[26] M. Confalonieri, A. Potena, G. Carbone, et al, Acute
respiratory failure in patients with severe community-acquired
pneumonia. A prospective randomized evaluation of
noninvasive ventilation, Am. J. Respir. Crit. Care Med. 160
(1999) 1585–1591.
[27] M. Levy, M.A. Tanios, D. Nelson, et al, Outcomes of patients
with do-not-intubate orders treated with noninvasive
ventilation, Crit. Care Med. 32 (2004) 2002–2007.
[28] R. Scala, S. Bartolucci, M. Naldi, et al, Co-morbidity and acute
decompensations of COPD requiring non-invasive positive-
pressure ventilation, Intensive Care Med. 30 (2004) 1747–1754.
[29] M. Holland, M. Alkhalil, S. Chandromouli, et al, Eosinopenia
as a marker of mortality and length of stay in patients admitted
with exacerbations of chronic obstructive pulmonary disease,
Respirology 15 (2010) 165–167.
[30] D.A. Bass, T.A. Gonwa, P. Szejda, et al, Eosinopenia of acute
infection: production of eosinopenia by chemotactic factors of
acute inﬂammation, J. Clin. Invest. 65 (1980) 1265–1271.
[31] D.A. Bass, Behaviour of eosinophil leukocytes in acute
inﬂammation, J. Clin. Invest. 55 (1975) 1229–1236.
[32] K. Abidi, I. Khoudri, J. Belayachi, et al, Eosinopenia is a
reliable marker of sepsis on admission to medical intensive care
units, Crit. Care 12 (2008) R59.
[33] H. Shaaban, S. Daniel, R. Sison, et al, Eosinopenia: is it a good
marker of sepsis in comparison to procalcitonin and C-reactive
protein levels for patients admitted to a critical care unit in an
urban hospital?, J Crit. Care 25 (2010) 570–575.
